United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 1,234 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,234 shares of the stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $132.29, for a total value of $163,245.86. Following the sale, the chief executive officer now owns 1,374 shares of the company’s stock, valued at approximately $181,766.46. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.08% during mid-day trading on Monday, hitting $130.95. The company had a trading volume of 442,519 shares. United Therapeutics Corporation has a one year low of $108.40 and a one year high of $169.89. The firm’s 50-day moving average price is $126.51 and its 200 day moving average price is $138.49. The company has a market capitalization of $5.90 billion, a P/E ratio of 9.19 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the consensus estimate of $3.12 by $0.77. The business had revenue of $370.50 million for the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The firm’s revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.02 EPS. Analysts predict that United Therapeutics Corporation will post $14.46 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 1,234 Shares” was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.wkrb13.com/markets/2286350/united-therapeutics-corporation-nasdaquthr-ceo-martine-a-rothblatt-sells-1234-shares.html.

A number of brokerages have recently commented on UTHR. Credit Suisse Group began coverage on United Therapeutics Corporation in a research report on Thursday, March 16th. They set an “underperform” rating and a $120.00 price objective for the company. Jefferies Group LLC reiterated an “underperform” rating and set a $116.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, March 17th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. UBS AG reiterated a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday. Finally, BidaskClub upgraded United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. United Therapeutics Corporation currently has a consensus rating of “Hold” and an average target price of $134.50.

Large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after buying an additional 4,632,287 shares in the last quarter. Norges Bank bought a new stake in United Therapeutics Corporation during the fourth quarter valued at approximately $63,975,000. AQR Capital Management LLC boosted its stake in United Therapeutics Corporation by 27.8% in the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after buying an additional 377,395 shares in the last quarter. Vanguard Group Inc. boosted its stake in United Therapeutics Corporation by 7.3% in the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock valued at $512,427,000 after buying an additional 256,514 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in United Therapeutics Corporation by 142.6% in the first quarter. BNP Paribas Arbitrage SA now owns 365,204 shares of the biotechnology company’s stock valued at $49,441,000 after buying an additional 214,687 shares in the last quarter.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286350/united-therapeutics-corporation-nasdaquthr-ceo-martine-a-rothblatt-sells-1234-shares.html

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.